Oncogene expression : Long-term compared with short-term survival in patients with advanced epithelial ovarian cancer

Obstetrical and Gynecological Survey

Volumn 92, Issue 1, 1998, Pages 88-93

  Goff, Barbara A ^a   Muntz, Howard G ^a   Greer, Benjamin E ^a   Tamimi, Hisham K ^a   Gown, Allen M ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE C ERB; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENES, P53; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; ONCOGENES; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TIME FACTORS;

EID: 0032125211     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1080/00006250-199807000-00018     Document Type: Article

References (31)

1. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
2. Felipe E, Del-Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prog-nostic value and relationship with response to chemotherapy. Cancer 1995;75:2147-2152.
3. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 1991;164:669-674.
4. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: Correlation with clinical outcome and response to chemotherapy. Br J Cancer 1995;72:361-366.
5. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-169.
6. Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Richard F, et al. C-erbB-2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 1995;64:146-151.
7. van der Burg ME, Henzen-Logmans SC, Foekens JA, Berns EM, Rodenburg CJ, van Putten WL, et al. The prognostic value of epidermal growth factor receptors determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: A pilot study. Eur J Cancer 1993;29A:1951-1957.
8. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumorsuppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-1022.
9. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992;140:145-153.
10. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-69.
11. Reles A, Schmider A, Press MF, Schonborn I, Friedmann W, Huber-Schumacher S. Immunostaining of p53 protein in ovarian carcinoma: Correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 1996;122:489-494.
12. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-306.
13. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-349.
14. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-1338.
15. Jordan PA, Kerns BM, Pence JM, Kohler MF, Bast RC, Jr., Kinney RB, et al. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1993; 99:736-740.
16. Isola J, Kallioniemi OP, Korte JM, Wahlstrom T, Aine R, Helle M, et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990;162:295-301.
17. Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC, Jr., Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1994;101:192-197.
18. Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM. Overexpression of Her-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor a in epithelial ovarian cancer. Eur J Gynaecol Oncol 1996;17:487-492.
19. Haerslev T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 1996;37:101-113.
20. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-248.
22. Altavilla G, Marchetti M, Padovan P, Marcato E, Onnis A. Predictive value of proliferative cellular nuclear antigen (PCNA) and Ki-67 antigen in advanced stage serous papilliferous ovarian cancer. Eur J Gynaecol Oncol 1996;17:524-528.
23. Veronese SM, Maisano C, Scibilia J. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 1995;15:2717-2722.
24. Kiyokawa T. Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994;13:311-318.
25. Sirvent JJ, Salvado MT, Santafe M, Martinez S, Brunet J, Alvaro T, et al. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (Ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 1995;10:531-539.
26. Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: Immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997;79:367-372.
27. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996;13:117-123.
28. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-693.
29. Noguchi T, Kitawaki J, Tamura T, Kim T, Kanno H, Yamamoto T, et al. Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol 1993;44:657-660.
30. Kieback DG, McCamant SK, Press MF, Atkinson EN, Gallagher HS, Edwards CL, et al. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res 1993;53:5188-5192.
31. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990;76:258-263.